SCHEMBL16474392

SCHEMBL16474392

CCOC(=O)c1cc2ccc(=O)n(-c3ccccc3)c2s1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.55
MAPT P10636 7/20 0.49
ALDH1A1 P00352 6/20 0.49
GAA P10253 3/20 0.49
SMN1; SMN2 Q16637 3/20 0.48
TDP1 Q9NUW8 2/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
NPC1 O15118 1/20 0.48
CASP3 P42574 1/20 0.48
RAB9A P51151 1/20 0.48
ATM Q13315 1/20 0.48
SENP7 Q9BQF6 1/20 0.48
SENP6 Q9GZR1 1/20 0.48
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
LMNA P02545 1/20 0.46
RECQL P46063 1/20 0.46
HSD17B10 Q99714 3/20 0.45
HPGD P15428 2/20 0.45
NPSR1 Q6W5P4 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16474393 0.89 HTT (0.44) KDM4EMAPTALDH1A1GAASMN1; SMN2
SCHEMBL16474387 0.88 ALDH1A1 (0.50) KDM4EMAPTALDH1A1GAASMN1; SMN2
SCHEMBL22421256 0.79 SMN1; SMN2 (0.41) KDM4EMAPTALDH1A1GAASMN1; SMN2
SCHEMBL27243768 0.76 KDM4E (0.64) KDM4EMAPTALDH1A1GAASMN1; SMN2
SCHEMBL16474394 0.76 MAPT (0.54) KDM4EMAPTALDH1A1GAASMN1; SMN2
SCHEMBL2960195 0.74 ALDH1A1 (0.56) KDM4EMAPTALDH1A1GAASMN1; SMN2
SCHEMBL1265759 0.74 MAPT (0.52) KDM4EMAPTALDH1A1GAASMN1; SMN2
SCHEMBL10079690 0.73 MAPT (0.51) KDM4EMAPTALDH1A1GAASMN1; SMN2
SCHEMBL5650136 0.73 MAPT (0.51) KDM4EMAPTALDH1A1GAASMN1; SMN2
SCHEMBL2783455 0.72 MAPT (0.50) KDM4EMAPTALDH1A1GAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10544161-B2 Anti-fibrotic pyridinones INTERMUNE, INC. (US) 2020-01-28 US disclosed
US-20190321343-A1 Anti-Fibrotic Pyridinones GENENTECH, INC. 2019-10-24 US disclosed
US-10376497-B2 Anti-fibrotic pyridinones INTERMUNE, INC. (US) 2019-08-13 US disclosed
US-20190144467-A1 ANTI-FIBROTIC PYRIDINONES GENENTECH, INC. 2019-05-16 US disclosed
US-10233195-B2 Anti-fibrotic pyridinones INTERMUNE, INC. (US) 2019-03-19 US disclosed
US-20180064692-A1 Anti-Fibrotic Pyridinones GENENTECH, INC. 2018-03-08 US disclosed
US-20180064692-A1 Anti-Fibrotic Pyridinones GENENTECH, INC. 2018-03-08 US disclosed
US-9675593-B2 Anti-fibrotic pyridinones INTERMUNE, INC. (US) 2017-06-13 US disclosed
US-9675593-B2 Anti-fibrotic pyridinones INTERMUNE, INC. (US) 2017-06-13 US disclosed
US-20170121345-A1 ANTI-FIBROTIC PYRIDINONES GENENTECH, INC. 2017-05-04 US disclosed
US-20170121345-A1 ANTI-FIBROTIC PYRIDINONES GENENTECH, INC. 2017-05-04 US disclosed
US-20160263090-A1 ANTI-FIBROTIC PYRIDINONES GENENTECH, INC. 2016-09-15 US disclosed
US-20160263090-A1 ANTI-FIBROTIC PYRIDINONES GENENTECH, INC. 2016-09-15 US disclosed
US-9359379-B2 Anti-fibrotic pyridinones INTERMUNE, INC. (US) 2016-06-07 US disclosed
US-9359379-B2 Anti-fibrotic pyridinones INTERMUNE, INC. (US) 2016-06-07 US disclosed
US-20140107110-A1 ANTI-FIBROTIC PYRIDINONES GENENTECH, INC. 2014-04-17 US disclosed
US-20140107110-A1 ANTI-FIBROTIC PYRIDINONES GENENTECH, INC. 2014-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180064692-A1 Anti-Fibrotic Pyridinones MMP1, COL1A1, COL2A1 KDM4E 2117/4885MAPT 4377/4885ALDH1A1 529/4885
US-10544161-B2 Anti-fibrotic pyridinones MMP1, COL1A1, COL2A1 KDM4E 2117/4885MAPT 4377/4885ALDH1A1 529/4885
US-20190321343-A1 Anti-Fibrotic Pyridinones MMP1, COL1A1, COL2A1 KDM4E 2117/4885MAPT 4377/4885ALDH1A1 529/4885
US-20140107110-A1 ANTI-FIBROTIC PYRIDINONES MMP1, COL1A1, COL2A1 KDM4E 2117/4885MAPT 4377/4885ALDH1A1 529/4885
US-20160263090-A1 ANTI-FIBROTIC PYRIDINONES MMP1, COL1A1, COL2A1 KDM4E 2117/4885MAPT 4377/4885ALDH1A1 529/4885
US-10233195-B2 Anti-fibrotic pyridinones MMP1, COL1A1, COL2A1 KDM4E 2117/4885MAPT 4377/4885ALDH1A1 529/4885
US-10376497-B2 Anti-fibrotic pyridinones MMP1, COL1A1, COL2A1 KDM4E 2117/4885MAPT 4377/4885ALDH1A1 529/4885
US-20170121345-A1 ANTI-FIBROTIC PYRIDINONES MMP1, COL1A1, COL2A1 KDM4E 2117/4885MAPT 4377/4885ALDH1A1 529/4885
US-20190144467-A1 ANTI-FIBROTIC PYRIDINONES MMP1, COL1A1, COL2A1 KDM4E 2117/4885MAPT 4377/4885ALDH1A1 529/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.